ã³ããðæ¥çš®ã¯çŽã¡ã«äžæ¢ãããªããã°ãªããªã ããã€ãç§åŠè ããŒã ããã®è¡æã®äºå調æ»å ±åæžã
60åã®å°é家ããæ§æããããã€ãã®ç§åŠè ããŒã ãããããæå 端ã®æè¡ãé§äœ¿ããŠâ çŸè¡ã®åã³ããã¯ã¯ãã³ã®å å ç©ãšâ¡æ¥çš®è ã®è¡æ¶²ãåæããå ±åæžç¬¬äžåŒŸïŒ
ãCOVID-19ðæ¥çš®ããã°ã©ã ã¯çŽã¡ã«äžæ¢ãããªããã°ãªããªãã[å šæèš³ïŒååïŒ]ã
ãã€ãCOVIDã¯ã¯ãã³åæã¯ãŒãã³ã°ã°ã«ãŒãã¯ãçŸè¡åã³ããã¯ã¯ãã³ã®å 容ç©ãæ¥çš®è ã®è¡æ¶²ãææ°ã®æè¡ãé§äœ¿ããŠèª¿æ»ããæåã®èª¿æ»çµæãäžè¬ã«å ¬éããã
1. COVID-19ã¯ã¯ãã³ã®å
šãµã³ãã«ãããäŸå€ãªãæ害ç©è³ªãæ€åºããããã
2. ã¯ã¯ãã³ãæ¥çš®ãããã¹ãŠã®äººã®è¡æ¶²ãµã³ãã«ã«èããå€åãèŠãããã
3. è質ããç²åã®ãšã³ãããŒãã®å®å®æ§ãé«ãã»ã©ãã¯ã¯ãã³ã®å¯äœçšãé »çºããã
1. COVID-19ã¯ã¯ãã³ã®å
šãµã³ãã«ãããããã€ãã®æž¬å®æ¹æ³ãçšããŠã以äžã®æåãæ€åºãããã
-èŠã€ãã£ãéã§ã¯ãå»çã¬ã€ãã©ã€ã³ã§ã®æ¯æ§ãããã
-補é è
ãã¯ã¯ãã³ã«å«ãŸãããšå®£èšããŠããªããã®ã
-ã»ãšãã©ã®å Žåãéå±ã§ããã
-æèŠéé¡åŸ®é¡ã§èŠããšãæ§ã
ãªå€§ããã®ç¹åŸŽçã§è€éãªæ§é äœã§ããããšããããã
-çµæ¶åãŸãã¯å解ããã»ã¹ã®çµæã§ãããšèª¬æããããšãã§ããªãã
-補é å·¥çšããã®æ±æã§ã¯èª¬æã§ããªãã
也ç¥ããã¯ã¯ãã³ã®é»åé¡åŸ®é¡åçãšXç·ã¹ãã¯ãã«ã®çµæ
2.ã¯ã¯ãã³æªæ¥çš®è
ãšã¯ã¯ãã³æ¥çš®è
ã®è¡æ¶²ãµã³ãã«ãæèŠéé¡åŸ®é¡ã§æ¯èŒãããšãããã¯ã¯ãã³ãæ¥çš®ãã人ã®è¡æ¶²ã«é¡èãªå€åãèŠããããããã¯ãããšããã®æç¹ã§ã¯æ¥çš®ã«äœãåå¿ã瀺ããªãã£ããšããŠããæãããªããšã ã£ããã¯ã¯ãã³ãšåããããªè€éãªæ§é ããã¯ã¯ãã³æ¥çš®è
ã®è¡æ¶²äžã«èŠãããã®ã ã人工ç¥èœïŒAIïŒã䜿ã£ãç»å解æã§ã¯ã¯ãã³æ¥çš®è
ãšéæ¥çš®è
ã®è¡æ¶²ã®éãã確èªãããã
ã¯ã¯ãã³æ¥çš®è ã®è¡æ¶²ãµã³ãã«ã®æèŠéé¡åŸ®é¡å
3.è質ããç²åãšã³ãããŒãã®å®å®æ§ã¯ãã¯ã¯ãã³ã®å¯äœçšãå·å®³ã®çºççãšå¯æ¥ãªçžé¢ãããããã®ãšã³ãããŒããå®å®çã§ããã»ã©çŽ°èå ã«æµžéããmRNAã®éãå€ããªããã¹ãã€ã¯èçœè³ªã®ç£çãè¡ãããããã®çµæã¯ã¯ã¯ãã³ã«ããå·å®³ã§æ»äº¡ãã人ã ã®æ€æ»ãè¡ã£ãç çåŠè ã®æèŠãšäžèŽããŠãããã¹ãã€ã¯èçœè³ªã¯æå·ããçµç¹ã§æ€åºããããç 究è ãã¡ã¯ãã¹ãã€ã¯èçœè³ªããèªäœãæ¯æ§ãæã£ãŠããã®ã§ã¯ãªãããšçã£ãŠããã
ã¯ã¯ãã³æ¥çš®ã®å¯äœçšãš(å³è©äžããã®)
è質åã®ç²åãšã³ãããŒãã®å®å®æ§
ãã€ãCOVIDã¯ã¯ãã³åæã¯ãŒãã³ã°ã°ã«ãŒãã¯ãã¯ã¯ãã³ã®å
容ãå¹æãåæããåŠéçãªäœæ¥éšäŒã§ãããã®ã°ã«ãŒãã¯ãå»åž«ãç©çåŠè
ãååŠè
ã埮çç©åŠè
ãè¬çåŠè
ã代æ¿å»çåŸäºè
ãå«ãç¬ç«ããç§åŠè
ã§æ§æãããåŒè·å£«ãå¿çåŠè
ãã¢ããªã¹ãããžã£ãŒããªã¹ãã«ãã£ãŠæ¯ããããŠããŸããåœã¯ãŒãã³ã°ã°ã«ãŒãã¯ãè¿ä»£çãªå»åŠçã»ç©çåŠç枬å®æè¡ã䜿çšãããã®çµæã¯äºãã«ç¢ºèªãè£å®ãåã£ãŠããŸããèµ°æ»åé»åé¡åŸ®é¡ïŒSEMïŒããšãã«ã®ãŒåæ£åXç·åå
åšïŒEDXïŒãã€ã³ã©ã€ã³ã»ãã©ã³ã¹ãã¡ãŒã»ã·ã¹ãã ã質éåææ³ïŒMSïŒãèªå°çµåãã©ãºãåææ³ïŒICPïŒãæèŠéé¡åŸ®é¡æ³ïŒBFMïŒãæèŠéé¡åŸ®é¡ïŒDFMïŒãè¡æ¶²ç»å蚺æãªã©ããŸãã人工ç¥èœãçšããç»å解æãè¡ã£ãŠããŸãã
åœã¯ãŒãã³ã°ã°ã«ãŒãã¯ãåæ§ã®ç 究ãè¡ã£ãŠããããã€ãã®åœéçãªã°ã«ãŒããšå¯æ¥ã«ååããªããç 究ãç¶ããŠããŸãããã®çµæãç§ãã¡ã®ã¯ã¯ãã³ã®åæçµæã¯ãçžäºæ€èšŒããããã®ãšèŠãªãããšãã§ããŸããã¯ã¯ãã³è£œé æ¥è
ãšããã€ãã§ã¯Paul Ehrlich InstituteïŒãã€ãé£éŠä¿å¥çã®ã¯ã¯ãã³èŠå¶ãæ
åœããæ©é¢ïŒãæºè¶³ã®ããçããåºãå¿
èŠããããŸããã¯ã¯ãã³ãšæ»äº¡äºæ
ãšã®å æé¢ä¿ã調æ»ããå¿
èŠãããã®ã§ãã
人åœãšå ¬å ±ã®å®å šã«å¯ŸããçŽæ¥çã§å·®ãè¿«ã£ãå±éºãåé¿ããããã«ãç§ãã¡ã¯ä»¥äžã®ããšãæ±ããŸãã
COVID-19ã¯ã¯ãã³æ¥çš®ããã°ã©ã ãçŽã¡ã«äžæ¢ãããããé¡ãããŸãã
ãäºå調æ»çµæã®æŠèŠã
åºæ
ç§ãã¡ã¯åœéçãªãããã¯ãŒã¯ãæã€ã¯ãŒãã³ã°ã°ã«ãŒãã§ãè¬å€åž«ãç§åŠè
ãæ°åŠè
ã代æ¿å»çåŸäºè
ãåŒè·å£«ããžã£ãŒããªã¹ããªã©60å以äžã®ã³ã¢ããŒã ããæ§æãããŠããŸããç§ãã¡ã¯ã人é¡å²äžæ倧ã®è¬çåŠçå®éšã§ãããšæããããã®å®éšã«å
ãåœãŠãããã«æè¡ãšå°éç¥èãçµéããŠããŸãã
ç§åŠãšå»åŠã®æŽå²ã«ãããŠã人é¡å
šäœã®ã»ãšãã©å
šãŠã®çš®ãå»åŠçãã€éºäŒåŠçãªå®éšã«ãããåæ°ã¯èª°ãæã¡ãŸããã§ãããããããã®ãããªå®éšãä»ã®çç©çš®ã«å¯ŸããŠææ¡ããããªããçš®ã®ä¿åã®ååã«åãããšãã説æã§åŽäžãããã§ãããã
ããããã®å®éšãæ¢ããããæ°é
ããªãããšããã®ããããã¯ã¯ãã³ã«ããå¯äœçšãå·å®³ãåäŸã®ãªãã»ã©å€ãããšãäžçäžã®åœå®¶çµ±èšã§ããããã®ã¯ã¯ãã³æ¥çš®ããã°ã©ã ã®åŸã«çŽãããªãéå°æ»äº¡çã瀺ããŠãããšããäºå®ã
ãããã®ããã°ã©ã ã®èŽåœçãªåœ±é¿ã¯ãã§ã«æããã§ããã«ããããããããã®åé¡ã«ä»å
¥ããæ€å¯ããŸã è¡ãããŠããªããšããäºå®ããã®ããã°ã©ã ã«å¯Ÿããæ¹å€è
ãå
¬ç¶ãšäžå·ãããææ¥ãããçµæžçã«ç Žæ»
ãããããŠããããšã
ãã®ãããç§åŠçã®æ
£äŸã«åããŠãç§ãã¡ã¯ãã®å ±åæžã®èè
ãšããŠå¿åã«ããããšã§èªåãã¡ãå®ãããšã«ããã®ã§ãã
ç§ãã¡ãçºèŠããããšã®å€ãã¯ããŸã äºåçãªãã®ã§ããããã®èª¿æ»çµæã¯ãæ¹å€çã«è°è«ãããååŒãããããã«æŽç·Žãããã¹ããã®ã§ãããŸãããŸã å€ãã®ããšãåæãããŠããŸããããçºèŠããããšã¯-ç§ãã¡ã¯ç¢ºä¿¡ããŠãã-éåžžã«éèŠã§ãã
ããã¯äžè¬å€§è¡ãç¹ã«ç§åŠçã«ç¥ããããªããã°ãªããªãããã®ããã«COVID-19ã¯ã¯ãã³ãå¥åº·ã«ããããå±éºæ§ãããåºãç解ãããããã®ã¯ã¯ãã³ã®ææªã®åœ±é¿ãã©ã®ããã«é²ãããšãã§ãããã«ã€ããŠç 究ããå¿
èŠããããŸãã
COVID-19ã¯ã¯ãã³ã«ã¯ãæ±æç©è³ªã«å ããŠãç®çãç¹å®ã§ããªãç©è³ªãäžè²«ããŠå«ãŸããŠããããšã確èªãããŠããŸãããã®ç®çã¯å®ãã§ã¯ãããŸããã
ç§ãã¡ãçºèŠãããããã®æåã®äžã«ã¯ãã¯ã¯ãã³ã¡ãŒã«ãŒãæåãšããŠèšèŒããŠããªããã®ãããããŸãã
ç§ãã¡ã¯ãã¯ã¯ãã³æ¥çš®è
ãšéæ¥çš®è
ã®å°éã®è¡æ¶²ãµã³ãã«ããã人工ç¥èœïŒAIïŒãã¯ã¯ãã³æ¥çš®è
ã®è¡æ¶²ãšéæ¥çš®è
ã®è¡æ¶²ã100ïŒ
ã®ä¿¡é ŒåºŠã§èå¥ã§ããããšãçªãæ¢ããŸããã
ãã®ããšã¯ãCOVID-19ã¯ã¯ãã³ã¯ã被æ¥çš®è
ã¯ãã®å€åãæèããããšãªãã被æ¥çš®è
ã®è¡æ¶²æåã«é·æçãªå€åãããããããšã瀺ããŠããŸãã
ç§ãã¡ã¯ãè¡æ¶²ã調ã¹ããã¹ãŠã®ã¯ã¯ãã³æ¥çš®è
ã®è¡æ¶²äžã«ãçµæ¶ã®åœ¢æãçºèŠããŸãããç§ãã¡ã¯ãããã®çµæ¶ã®åæãç¶ããŠããŸããç§ãã¡ã調ã¹ããã¹ãŠã®ã±ãŒã¹ã§ãèµ€è¡çã®ã«ãŒããŒåœ¢æã芳å¯ããããŸããã¯ã¯ãã³æ¥çš®è
ã®ããŸããŸãªçš®é¡ã®çŽ°èãç°åžžã«éã厩å£ããã®ããã°ãã°èŠ³å¯ãããã
ç§ãã¡ã¯ãåè硬åãCOVID-19ã¯ã¯ãã³ãæ¥çš®ãããæ¹ãçŽé¢ããå€ãã®é·æç圱é¿ã®ã²ãšã€ã«éããªããšãã仮説ãæ€èšããŠããŸãããã®ä»®èª¬ã確èªãããã°ãå¥åº·é¢ã§ã瀟äŒçµæžé¢ã§ãããã®åœ±é¿ã¯åºç¯ãªãã®ã«ãªãã§ãããã
å
ç«ç³»ã匱ããèªå·±å
ç«çŸæ£ãåè硬åçãªã©ã¯èåšé害ãé«è¡å§ãå¿çæ¢å¡ãç¥çµå€æ§çŸæ£ãçãªã©ãåŒãèµ·ããã寿åœãçž®ããé°æ¹¿ãªç
æ°ã§ããçŸæ£ãã¿ãŒã³ãäžæ確ã§ããããšãããCOVID-19ã®äºé²æ¥çš®ãå æé¢ä¿ãæã€å¯èœæ§ãæœãã§ããŸãã
å°ãªããšããä»åã®èª¿æ»çµæã®ã²ãšã€ã²ãšã€ããã¯ã¯ãã³ãåççãªçãããé€å€ããããã«ãCOVID-19ã¯ã¯ãã³æ¥çš®ããã°ã©ã ã®å³æåæ¢ãããããçã§ãã
å®éãç§ãã¡ããã§ã«èªèããŠããå±éºæ§ãèæ
®ããã°ãCOVID-19ã®ã¯ã¯ãã³æ¥çš®ããã°ã©ã ã¯ãã£ãšåã«äžæ¢ãããã¹ãã ã£ãã®ã§ãã
ãã®ç®æšãéæããããã«ã¯ãç§ãã¡ã®ç 究ææãã¡ãã£ã¢ã«ãã£ãŠé«ãã¬ãã«ã§å ±éãããå¿
èŠãããã®ã§ãã
ãã€ãCOVIDã¯ã¯ãã³åæã®ããã®ã¯ãŒãã³ã°ã°ã«ãŒã
ââââââââââââââââââââââââââ-
ãã¯ããã« (äžéšçç¥)ã
2020幎3æ以éãç§ãã¡ã¯åäŸã®ãªãæ¿æ²»çç¶æ³ã«çœ®ãããŠããããããããã®å ±åæžã®å
容ã¯éåžžã®ãã¢ã¬ãã¥ãŒããã»ã¹ãçµãŠããŸãããåœéçãªãããã¯ãŒã¯ã®äžã§ç§ãã¡ã®çºè¡šã«æ¹å€çãªç®ãåãããã£ãŒãããã¯ããŠãããæ°äººã®åªç§ãªä»²éã«æè¬ããŸãã
åæã¯ãå€ãã®åœã®æ§ã
ãªæ©é¢ã«ãããŠãå€æ§ãªæ¹æ³ã§è¡ãããŸããã
åºçºç¹ã¯ãã¯ã¯ãã³æ¥çš®è
ãšéæ¥çš®è
ã®ã¯ã¯ãã³ãšè¡æ¶²ã®å
容ç©ã®é¡åŸ®é¡èŠ³å¯ã§ãããééå
é¡åŸ®é¡ãäœçžå·®é¡åŸ®é¡ãæèŠéé¡åŸ®é¡ãªã©ãããŸããŸãªå
é¡æ³ãçšããŠã¯ã¯ãã³ãšè¡æ¶²ã芳å¯ããŸããããããã®æ¹æ³ã®å
šãŠã«ãããŠã2æ¡ÎŒmã®ç¯å²ã§ãæ§ã
ãªè£œé æ¥è
ã®æ§ã
ãªãããã§ãé©æ£è£œé åºæºïŒGMPïŒã®èŠåã«åŸã£ãŠèš±å®¹ã§ããªãã»ã©å€§ããªç©äœã瀺ãããŸããã
ãã€ãåœå
ã§ã®ã¯ã¯ãã³ã®åæããã®ãããããã³ãªãªãŒã¹ã¯ããã®ä»»åã®ç®¡èœæ©é¢ã§ããæ¿åºæ©é¢ãããŒã«ã»ãšãŒãªãã¯ç 究æïŒPEIïŒã®è²¬ä»»ã§ããããšãææããŠãããŸããPEIããã®è²¬åãååã«æãããŠãããããŸãå¿
èŠãªéææ§ã確ä¿ãããŠããªãããšã¯æããã§ãã
äžè¬åžæ°ã¯ããã®ããšãã»ãšãã©æèããŠããŸããã
ãã®ãããªè²¬ä»»ããæ©é¢ã®è·åæ æ
¢ãããç§ãã¡ç¬ç«ããç§åŠè
ã¯ããããã®ã¯ã¯ãã³ã®ãµã³ãã«ãåæããããã«éãŸãããšã«ããã®ã§ãã
ç§ãã¡ã®èŠçŽã¯åžžã«æ¹èšãããåæçµæã«ãã£ãŠè£è¶³ãããŸãããã¯ã¯ãã³ã®åæã«éå®ããããã®ã§ã¯ãããŸããã
ââââââââââââââââââââ
ãæŠèŠã
1. COVID-19ã¯ã¯ãã³ãæ¥çš®ãã被éšè ãšæ¥çš®ããŠããªã被éšè ã®è¡æ¶²ãæèŠéé¡åŸ®é¡ã§æ¯èŒèŠ³å¯é·å¹Žã«ãããã1äžä»¶ãè¶ ããæ§é åè¡æ¶²åæãå®æœãããŠãããCOVID-19ã¯ã¯ãã³æ¥çš®ã«é¢é£ããŠ48人ã®ã¯ã¯ãã³æ¥çš®è ãæ€æ»ãããããããã®æ£è ã«ã¯äŸå€ãªãïŒã¯ã¯ãã³æªæ¥çš®è ã§ã¯1äŸã芳å¯ãããªãã£ãç¹ç°æ§ãèªããããããŸããã¯ã¯ãã³æ¥çš®è ã®è¡æ¶²ã¯ïŒç åæ§ïŒããããã°ãã°é«ç åæ§ã®èšåºåãšé¡äŒŒããçŸè±¡ã瀺ããããã®ãããªèŠ³å¯çµæã¯ãæèŠéé¡åŸ®é¡ã䜿çšããŠããä»ã®èŠ³å¯è ãæ²»çè ã«ãèªããããŠãããéºäŒåããŒã¹ã®ã¯ã¯ãã³ã®çå®ã¯äœãïŒããããå®éããã®ã¯ãŒãã³ã°ã°ã«ãŒããèšç«ãããäž»ãªçç±ã§ããã
2.COVID-19ã¯ã¯ãã³äžã®éå±ç²å
ãã¯ã¿ãŒããã³mRNAããŒã¹ã®COVID-19ã¯ã¯ãã³ã«ãããéå±æ±æç©è³ªã®èª¿æ» - äºåççµæ [BioNTech/PfizerãModernaããã³Astra Zenecaã®COVID-19ã¯ã¯ãã³ã®ãã€ã¢ã«]ããæ±æç©è³ªã®å¯èœæ§ãç¹å®ããããã«èµ°æ»é»åé¡åŸ®é¡(SEM)ããã³å¯Ÿå¿ãããšãã«ã®ãŒåæ£Xç·åå
æ³(EDX)ã§èª¿æ»ãããšãããéå±ç²åãçºèŠãããã
3.COVID-19ã¯ã¯ãã³ã®æšæºåæã®äºåçãªçµæ
âŸïžããå®å®ããããè質ã«ããå¯äœçšã®å¢å ãâŸïžããè質ã®å解ã«ããçµæ¶åã®åœ±é¿(äŸ:ã³ã¬ã¹ãããŒã«)ãâŸïžppmç¯å²ã®éå±äžçŽç©ãâŸïžã«ã«ã·ãŠã ãšã¢ã«ãããŠã ã«ããäžç¹å®å€æ°ã®äžçŽç©ãå
æãæ¹æ³ïŒSEM-EDSã質éåæè£
眮(MS)ã
4.ã¢ãã«ãäžã®ã¢ã³ãã¢ã³
倩ç¶ç±æ¥ã®ã¢ã³ãã¢ã³ã¯åŒ·æ¯æ§ïŒã¢ãã«ãã¯ã¯ãã³ã®ç¡æ©è³ªåæã§ã¢ã³ãã¢ã³ãæ€åºãããŸãããã¢ãã«ãåã³BioNTech/Pfizerã¯ã¯ãã³ãèªå°çµåãã©ãºã(ICP)åæè£
眮ã§åæããçµæãã¢ã³ãã¢ã³ä»¥å€ã®å
š41å
çŽ ã¯ããããã®æ€åºéç(DL)以äžã§ãããDLã¯è©Šæéã«èµ·å ããé«DLã¯è©Šæéãå°ãªãããã§ãã£ãã
5.ã¢ã³ãã¢ã³ã®äºåè©äŸ¡ãæ§ã
ãªåé¡ç¹
ã¢ã³ãã¢ã³ã¯å€©ç¶ã«ååšãæ¯æ§ã匷ãããã¢ãã«ãã®æ¿åºŠã§ã¯æ¯æ§ã¯ãªãã¯ãã§ããããããã¢ãã«ãäžã®åå䟡ãäžæã§ãããæåè«ã»æå¯çè«äœçšãéèŠãªä»£è¬æ©èœãé»å®³ããå¯èœæ§ããããã¢ãã«ãäžã®åå䟡ã§æãå¯èœæ§ã®é«ã5䟡ã®ã¹ããã°ã«ã³ã³é
žãããªãŠã ãéçµå£ïŒæ³šå°ïŒæäžãããšãåãæ°ãååãçèçãé çãåç ãå¿é»å³å€åãªã©ã®å¯äœçšãèµ·ããå¯èœæ§ããããé·ææäžã«ããèºçãè¡çæ°é害ãèæ©èœé害ãéãé害ã¯äž»ã«èèãšå¿èã§çºçããããããã¯ããããã¯ã¯ãã³æ¥çš®åŸã«èŠ³å¯ãããŠããèšåºäºè±¡ã
6.ãããªã«ããèšé²ã
ã¯ã¯ãã³ã®ãããªã§ã¯ãZeiss Axiolabé¡åŸ®é¡ã䜿çšããŠãBioNTech/Pfizerã®Comirnatyã¯ã¯ãã³ã®æ§ã
ãªããããæ€æ»ããŸããããããªã®æåŸã«ã¯ãã¯ã¯ãã³æ¥çš®ãåãã人ã®è¡æ¶²ãµã³ãã«ãããã€ãæ ã£ãŠããããã®äžã«ã¯ã¯ãã³ã«å«ãŸãããã®ãšé¡äŒŒããæ§é ãèŠã€ãããŸãããæ¯èŒã®ããã«ã2çš®é¡ã®ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ãå¥ã®ãããªã§æ€èšŒããŠã¿ãŸããããã®éãã¯äžç®çç¶ã§ããåç»ã¯ãã¡ãã§ã芧ããã ããŸãïŒhttps://t.me/agimpfstoffe
â»åœè©²æ åã¯ãã¶ããã¡ããšæãããŸãã
ðhttps://odysee.com/@drsambailey:c/nz-scientist-examines-pfizer-jab-under-the-microscope:6
7.COVID-19ã®æ¥çš®ã«ãããè¡æ¶²ã«å€åã¯ãããïŒ
人工ç¥èœãçšããç»å解æã«ããæ¯èŒåæãã¯ã¯ãã³æ¥çš®è
ãšéæ¥çš®è
ã®è¡æ¶²ãæ瀺ããäžæ¬¡çãªè©Šã¿ã§ã¯ãè¡æ¶²ã«å€åãããããšã瀺ããããããã¯ãã¯ã¯ãã³æ¥çš®è
ãšéæ¥çš®è
ã®è¡æ¶²ã®ç»åãçšããŠåŠç¿ããã人工ç¥èœ(AI)ã«ãã£ãŠç€ºããããã®ã§ããããããã¯ã¯ãã³æ¥çš®åŸãç¶ãã®ãããã€ãŸã§ç¶ãã®ãã¯äžæã§ã2022.5.1çŸåšããµã³ãã«æ°ããŸã å°ãªããã調æ»ã«ã¯éçããããŸãããã®å°ããªãµã³ãã«ã§ããã¹ãŠã®ã±ãŒã¹ã§å€åã瀺ãããããšããŸããããç¶æ³äžã§ã¯COVID-19ã¯ã¯ãã³æ¥çš®ã«ãã£ãŠäººéã®èåšãå€åããå¯èœæ§ããããšããäºå®ã®éèŠæ§ããã決å®çãªçµæãå
¬è¡šããåã«ãç§åŠçã®ä»ã®äººã
ã«ãã®çµæã確èªãããã蚎ããŠããŸãã
ââââââââââââââââââââ
ãCOVID-19ã¯ã¯ãã³ãæ¥çš®ãã被éšè
ãš
æªæ¥çš®è
ã®è¡æ¶²ã®æ¯èŒèŠ³å¯ã
æèŠéé¡åŸ®é¡ã«ããè¡æ¶²åæã¯ãè£å®ä»£æ¿å»çã®åéã§å®èšŒããããšããã³ã¹ã«åºã¥ãæ¹æ³ã§ããç¹æ®ãªæèŠéãªã€ã«ã³ã³ãã³ãµãŒãåããé«è§£å床é¡åŸ®é¡ã䜿çšããŸããå®éã2001幎9æ11æ¥ã«ãã¥ãŒãšãŒã¯ã§èµ·ããããäºä»¶ã®åšèŸºã«ãã人ã
ãå«ãäžçäžã®1äžäººä»¥äžã®äººã
ããŸããªãŒã¹ãã©ãªã¢ãã¢ã¡ãªã«ãã«ããããšãŒãããããã®äººã
ã察象ãšããçã¯ãªããã¯ã§ã12幎éã«ãããæèŠéé¡åŸ®é¡ã«ããè¡æ¶²ã¹ã¯ãªãŒãã³ã°ã®çµéšãæããŠããŸãã
æèŠéé¡åŸ®é¡ã«ããè¡æ¶²æ€æ»ã§ã¯ãã©ã®ããã«åæãè¡ãããã©ã®ãããªããšãè¡ãããŠããã®ã§ããïŒ
æèŠéé¡åŸ®é¡ã¯ãè¡æ¶²ãå®æ§çã«åæããæ¹æ³ã§ããåç©åŠè
ã§ãã现èåŠè
ã§ããã£ããšã³ãã«ã©ã€ã³ææ(1872-1968)ã®ç 究ã«ç«¯ãçºãã圌ã¯ãã®æè¡ãè¡æ¶²ãšãã®æåã®ç 究ã«éäžçã«äœ¿çšããŸããã
ä»æ¥ãæèŠéé¡åŸ®é¡ã¯ç§åŠçæ ¹æ ã«åºã¥ãæ¹æ³ãšããŠäžçäžã§äœ¿çšãããŠããŸããçããè¡æ¶²ãçŽæ¥ãå³åº§ã«åæããããšãã§ããã圢ç¶ã倧ããã匟åæ§ãšãã£ãè¡çã®è³ªã芳å¯ãã现èå€æ¶²äžã®ååžã調ã¹ãããšãã§ããŸããããã«ã现èãå¯çè«ã«ããæ±æã®å
åãæ€åºããããšãã§ããŸãããŸããè
æãå£åã®éçšãåæãããŸãããã®æè¡ã«ãããæ°Žåãæ é€ã®æåéãéæ¥çã«è¡šçŸããããšãã§ããŸãã
ã¹ã©ã€ãäžã®è¡æ¶²æåã®ã©ã€ããµã€ã¯ã«ã¯æçµçã«å解ããããŸã§ã®æéçµéã芳å¯ããåæã»è©äŸ¡ããŸãã
æèŠéè¡æ¶²æ€æ»ã®å®æœã«éããŠäžè¬çã«é©çšãããåºæºã»æ€æ»æ¡ä»¶ã¯åžžã«åãåºæºã§å®æœããå¿
èŠããããŸãã
æ£è
ã¯çµ¶é£ç¶æ
ã§æ€æ»ã«èšãããš(å°ãªããšã8æé以äžé£äºãæ§ããããš)ãæ€æ»åã«ã³ãã1æ¯ã®æ°Ž(200ml)ã飲ãããšãæ€æ»å®€ã¯ãæŸå°ç·ãå°ãªããè¡ççã«æž
æœã§ãæºåž¯é»è©±ãªã©ã®é害ç©ããªãå Žæã§ãªããã°ãªããŸããããŸããæµæ°Žã§æãæŽããŸãïŒç³é¹žãªãïŒã次ã«ãã©ã³ã·ã³ã°ããã€ã¹ã䜿çšããŠãæå
ã泚ææ·±ãç©¿åºããŠè¡æ¶²ïŒæ¯çŽ°è¡ç®¡è¡ïŒãäžæ»Žæ¡åããæåã®äžæ»Žã¯ç¶¿æ£ã§æããæãåããŸããè¡çãžã®æ©æ¢°çæå·ãé¿ããããã2滎ã®è¡æ¶²ãã¹ã©ã€ãã«æ
éã«æ»Žäžãã(è¡æ¶²ã®æ»Žäžã¯ã¹ã©ã€ãã«ãé£ã³ã€ããããã«ãã)ãããã«ããè¡æ¶²ãã¹ã©ã€ãã«æé©ã«ç§»ãããã次ã«ãã«ããŒã¹ãªããã䜿çšããŠãã¹ã©ã€ãããäœãè·é¢ã§è¡æ¶²ãµã³ãã«ãéåžžã«æ³šææ·±ãèŠããŸãã
âªïžè¡æ¶²ãåæããŸãã
è¡æ¶²ã滎äžããã¹ã©ã€ãã¯ãçŽã¡ã«æèŠéé¡åŸ®é¡ã§åæãããŸãã100åã®åçã§ä»¥äžã®ãããªããããã®æŠèŠ³ãå¯èœã§ãã
- è¡çãšè¡æŒ¿ã®æ¯ç
- æ§ã
ãªè¡çã®åœ¢ãšæ°
- è¡çã®éåæ§ã掻æ§åºŠ
1,000åã®åçã§è¡æ¶²ã®ç¶æ
ãè©äŸ¡ 400åã®åçã§è©äŸ¡ããããšããããŸãã
çµæã¯èšé²ãããŸãã
1æéåŸã2æéåŸãããã«ééããããŠãã¹ã©ã€ãäžã®è¡æ¶²ã芳å¯ããŸãã
- è¡çã®åœ¢
- è¡çã®åœ¢ è¡çã®æŽ»æ§
è¡æ¶²æåãå®å
šã«åŽ©å£ãããŸã§ããã®ã¢ãã¿ãªã³ã°æé ãç¶ç¶ããã
âªïžäºåçæèŠã®ãŸãšã
è¡çã®åãã ãã§ãªãã现èèã®åœ¢ãå®å®æ§(å£åãããŸã§)ãè¡çã®æŽ»æ§ãçåæé(æ°æéãã6é±é)ã现èå€æ¶²ã®ããŸããŸãªç
ççç¹åŸŽãèŠãããšãã§ããã
é·å¹Žã«ããããç§ãã¡ã®èšºçæã§ã¯ãæ£è
ã®è¡æ¶²äžã®è»œéå±ãšééå±ã®äž¡æ¹ã®è² è·ãå¢å ããŠããããšã芳å¯ããŠããŸãããããã¯ãç°å¢è©Šéšæããã®èªçºè©Šéšãåå
å
床èšã«ãã枬å®ã§èšŒæã»ç¢ºèªããããšãã§ããŸãã
ã¯ã¯ãã³æªæ¥çš®ã®å¥åº·ãªè¢«éšè
ã®è¡æ¶²ã¯ãããããªãã©ãŠã³ååéåãè¡çã®æ確ãªèª¿åååžãæ確ãªçŽ°èå€ãããªãã¯ã¹ã«ãã£ãŠç¹åŸŽã¥ããããŸãïŒå³1ïŒã
ã¯ã¯ãã³æ¥çš®ãåããæ£è
(ç¹ã« BioNTech/Pfizer åã¯ã¢ãã«ãã®ã¯ã¯ãã³ãæ¥çš®ããæ£è
)ã®è¡æ¶²ã¯ãäž»ã«ä»¥äžã®éãã« ãã£ãŠéç«ã£ãŠããã
- ãããŸã§ã¯ã¯ãã³ãã®ãã®ã«ããèŠãããªãã£ãæ°ããæ§é (å³3ã4ã5) (å¯å°ãããã¯ã¯ãã³ãå°ãªããšã3ãããã12æ¬ä»¥äžã®ãã€ã¢ã«ãåæããã)ãäŸãã°é·æ¹åœ¢ãæ£æ¹åœ¢ã®çµæ¶åœ¢ç¶ãã¹ãã€ã©ã«ãªã©ããã®çš®ã®æ§é ã¯ãããŸã§ããè¡æ¶²äžã«çºèŠãããããšããªãããããã®æ§é ã¯ãBioNTech/Pfizer瀟ã®Comirnatyã¯ã¯ãã³(ãµã€ãºã¯æ倧25ÎŒmãèµ€è¡çã®çŽåŸã¯çŽ7.5ÎŒm)ã§æãé »ç¹ã«èŠãããŸãã(å³4ã2段ç®å·Š)ã
- èµ€è¡çã®çŽ°èèãæããã«å€åœ¢ããŠããããã®ãããªå€åœ¢ã¯ãéåžžãæ
¢æ§çŸæ£ãé床ã®å€æ§çŸæ£ã®ãã人ã«ããèŠãããªã(å³4ã2段ç®å·Š)ã
- ãŸããå°ããªè¡ç®¡(40ÎŒmçšåºŠãŸã§)ãå¡ãè¡æ (ã©ã¡ã©ç¶ã®æ§é ç©)ãé »ç¹ã«èŠ³å¯ããããã¯ã¯ãã³æ¥çš®è
ã®è¡æ¶²ç²åºŠ(è¡æ¶²ã®æµåæ§ã®äœäž)ã¯ãèããäžæããŸããéåžžãè³æ¢å¡ãè¡æ çã®ãªã¹ã¯ããã人ã ãã«èŠãããçŸè±¡ã§ãã(å³4å·Š2段ç®ïŒã
- å解éçš(å¥åº·ãªäººã®è¡æ¶²ã¯ã¹ã©ã€ãäžã§äœæ¥ãçããŠãã)ã芳å¯ãããšããã®é²è¡ã¯æ©ããæã«ã¯æ°æéããçããããªãããšããããŸãã
- ããããèµ€è¡çã®è
æéçšããããããŽãŒã¹ãã»èµ€è¡çã®åœ±ãèŠãããšãã§ããŸããããã¯éåžžãé床ã®æ
¢æ§ççéçšãæ
¢æ§çŸæ£æ£è
ã«ã®ã¿èŠãããçŸè±¡ã§ãïŒå³2ã5ïŒã
- å°è±¡çãªã®ã¯ãã¯ã¯ãã³æ¥çš®ãåãããã©ãããç¥ãå¿
èŠããªãããšã§ããæ£è
ã®è¡æ¶²ã«é¡èãªå€åãèŠãããããšã§æ¥çš®ãèªèããããšãã§ããã®ã§ãã
å€ãã®æ£è
ãšã®çµéšãããã¯ã¯ãã³æ¥çš®è
ãšéæ¥çš®è
ã®è¡æ¶²ã«ã¯æããã«å€§ããªç°è³ªæ§ãããããšãå ±åããããé¡åŸ®é¡ã¯åãã€ããªããæž
æœãªäœæ¥ãè±å¯ãªçµéšããããŠæ¡è¡æã®æ¡ä»¶ãåºæºãåãã§ããããšãããã®éããæ確ã«æ€åºããããã®åææ¡ä»¶ãšãªãã®ã§ãã
ã¯ã¯ãã³æ¥çš®ãåãã人ã®è¡æ¶²ã®ç»åã¯ãéåžžã«å¿é
ã§ããç°å¢å»åŠã§ã¯ãäŸãã°ééå±ãçµåçµç¹ãè³ã«å
¥ã蟌ãããšãç¥ãããŠãããã¯ã¯ãã³ãšãã®æè¡ã«ãããŠã¯ããããã®ç©è³ªãçäœå
šäœã«åºããå¯èœæ§ããããšçµè«ããããåŸãŸããã
å³2ïŒ2ã€ã®ç»åã¯ã³ãã«ããã£ãæ¥çš®ãã52æ³ç·æ§ã®ã¯ã¯ãã³æ¥çš®è
ã®è¡æ¶²äžã«ç°åžžãªç©äœãããããšã瀺ãããã®è¢«éšè
ã¯ãæ¿ããç²åŽæãšåŠæ æã蚎ããã
ãã®åçã¯BioNTech/Pfizerã®Comirnatyå液ã®ãã®ã§ãç°ãªããããã«åæ§ã®ç©äœãåã£ãŠããŸãããã®çš®ã®ç©äœã¯æ±ºããŠç¹æ®ãªãã®ã§ã¯ãªããå€ãã®ç¬ç«ãã芳å¯è ã«ãã£ãŠãç°ãªãè¡æ¶²ãµã³ãã«ãã¯ã¯ãã³ã®ãµã³ãã«ã§ç¹°ãè¿ã芳å¯ãããŠããã®ã§ãåŸããã®æ±æã®çµæã§ããããšã¯æ¥µããŠããããŸãããèšããŸã§ããªãããã®ãããªå€§ããªç©äœã¯ããã®å€§ããããã«ãè¡ç®¡å ã®è¡æ¶²åŸªç°ã®ä¹±ãã«ã€ãªããå¯èœæ§ããããŸãã
å³3ïŒè¡äžçµæ¶ãšã¯ã¯ãã³äžã®çµæ¶ã®æ¯èŒãå·Šã¯ã³ãã«ããã£ïŒBioNTech/PfizerïŒãæ¥çš®ãã被éšè
ã®è¡æ¶²äžã«çµæ¶ã®åœ¢æãèŠãããå³ã®ç»åã¯ã³ãã«ããã£ã®ã¯ã¯ãã³ã«ããã®çš®ã®çµæ¶ãèŠãããããšã瀺ããŠããŸãããã ããå®æçã«èŠ³å¯ã§ããè¡äžã®é«ãçºççãåŒãèµ·ããã«ã¯ãã¯ã¯ãã³1ååã®éã§ã¯äžååã§ããããšã«æ³šæããå¿
èŠããããŸãããããã£ãŠãã¯ã¯ãã³ã¯èåšæ©èœãäŸãã°èæ©èœã«ã圱é¿ãäžãããã®çµæãããã®æ§é ç©ãååšããããšã«ãªããšèããã®ã劥åœã§ãããã
å³4ïŒã³ãã«ããã£(BioNTech/Pfizer)ãæ¥çš®ãã被éšè ã®è¡æ¶²äžã«èŠãããæ§ã ãªç°åžžçŸè±¡ãç©äœã瀺ã4æã®ç»å
å³5ïŒã¢ã¹ãã©ãŒãã«ãæ¥çš®ãã被éšè ã®è¡æ¶²äžã«ããè¡æ¶²ã«å«ãŸããªãç©äœãåºçŸããŠãããå·Šãšäžå€®ã®ç»åã¯1000åãå³ã®ç»åã¯100åã®åçã§è¡æ¶²ãæ®åœ±ã
å³6ïŒãžã§ã³ãœã³ã»ãšã³ãã»ãžã§ã³ãœã³ã®ã€ã³ã»ã³ãã¯ã¿ãŒã¯ã¯ãã³ã®ç°åžžãªããžã§ã¯ãããªãããã®çš®ã®ç©äœã¯ãã¹ãŠã®ãµã³ãã«ã§èŠã€ãã£ãããã§ã¯ãªãã
å³7ïŒBioNTech/Pfizer瀟ã®Comirnatyã¯ã¯ãã³ã«ã¯ãå€æ§ã§å€æ°ã®ç°åžžãªç©äœãèŠããããèšå€§ãªæ°ã®çµæ¶æ§ã®æ¿ç¶ç©ã圢ç¶ã¯äžçŽç©ãšã¯è§£éããããããããã¯ãã¹ãŠã®ãµã³ãã«ã«èŠåçã«ããã€å€§éã«åºçŸããŠããã
å³8ïŒComirnaty(BioNTech/Pfizer)äžã®ãããã®ç©äœã¯äžçŽç©ã§ããå¯èœæ§ãé«ãããã®èµ·æºãæããã«ããå¿
èŠãããã倧ããã¯50ÎŒmãè¶
ãããã®ãããã
å³9ïŒã¯ã¯ãã³æ¥çš®ãåãã人ã®èºã®çµç¹ãæ®åœ±ããç»åã§ãè€å±ææ§ã®ç²åã確èªã§ããŸãããã®çš®ã®ç²åã¯ã人äœã«ãšã£ãŠç°ç©ãšã¿ãªããããå³8ïŒå·ŠäžïŒã®ç©äœãšã®èããé¡äŒŒæ§ã«æ³šç®ã[åºå
žïŒArne Burkhardtãã«ããæäŸã2022幎]ã
âââââââââââââ-ââæ¬å ±åæž[åå]E N D
é·æããèªã¿ããã ãããããšãããããŸãããðð»ââïž
äºå調æ»ã§ããå€ãã®æ€èšŒãèŠããŸãããæ¥çš®è
ã®äœå
ã§èµ·ããŠããäºã®ããŸãã«é倧äºå®ã«æŠæ
ãèŠããŸãã
ãã®å
容ã¯ãã²ç§åŠè
ãå»çåŸäºè
ã®çæ§ã ãã§ãªãèªæ²»äœãåŠæ ¡ãåœäŒè°å¡ãç¹ã«åã©ãã®ã¯ã¯ãã³æ¥çš®ã«é¢ããåäœã«æ¡æ£ããŠããã ãããæããŸãã
ããããã®äºå®ãæ¥æ¬ã®å ¬çæ©é¢ã«ãã£ãŠèª¿æ»ããå®å šæ§ã確èªããããŸã§ã³ããã¯ã¯ãã³æ¥çš®ã¯å³å»å šé¢äžæ¢ãã¹ããšèããŸããã
â»ç¿»èš³ã¯DeepLãçšããæç« ãæŽããŸããã
â»æ¬ããã°ã¯å°é家ãå»çåŸäºè
ã®æ¹ã«ããèªã¿ããã ãçºã»ãŒå²æããŠããããèªã¿ã«ããããšæããŸãã
ççž®çãå¥éã¢ããèŽããŸãã
â»åŸåã¯ã¯ã¯ãã³ã«å«ãŸããæ§é ç©ã®ããæ¬æ Œçãªè§£èª¬ãšãªã£ãŠããŸã(ä»ã®æèš³ãäºå®ã¯ãããŸãã)ã
ããµããŒãã¯äžèŠã§ã (ãªã³ã¯ãå€ãããšãåºæ¥ãŸãã)ãééã¯æŽããªã䞻矩ã§ãã®ã§å®ãããé¡ãããŸãã
ã·ã§ããã³ã°ãªå 容ã§ãã倧äžå€«ãæ°ãèœãšãã察çããŸãããïŒããã€ãããããšãããããŸãðº è¯
ãã®èšäºãæ°ã«å ¥ã£ãããµããŒããããŠã¿ãŸãããïŒ